| 000 | 01805 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515211434.0 | ||
| 264 | 0 | _c20100525 | |
| 008 | 201005s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/cncr.25029 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHainsworth, John D | |
| 245 | 0 | 0 |
_aOxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. _h[electronic resource] |
| 260 |
_bCancer _cMay 2010 |
||
| 300 |
_a2448-54 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 | _aCapecitabine |
| 650 | 0 | 4 |
_aDeoxycytidine _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms, Unknown Primary _xdrug therapy |
| 650 | 0 | 4 |
_aOrganoplatinum Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aOxaliplatin |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRetreatment |
| 650 | 0 | 4 | _aSalvage Therapy |
| 700 | 1 | _aSpigel, David R | |
| 700 | 1 | _aBurris, Howard A | |
| 700 | 1 | _aShipley, Dianna | |
| 700 | 1 | _aFarley, Cindy | |
| 700 | 1 | _aMacias-Perez, Ines M | |
| 700 | 1 | _aBarton, John | |
| 700 | 1 | _aGreco, F Anthony | |
| 773 | 0 |
_tCancer _gvol. 116 _gno. 10 _gp. 2448-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.25029 _zAvailable from publisher's website |
| 999 |
_c19576779 _d19576779 |
||